| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.36 | 7e-10 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.22 | 3e-08 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.32 | 3e-07 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-06 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.2 | 3e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.29 | 4e-06 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.2 | 6e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.27 | 7e-06 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.17 | 9e-06 |